ORPHA:2334
Autosomal dominant keratitis
Also known as: Hereditary keratitis
Publications
22,681
Trials
0
Interventional, condition-specific
Researchers
234
Distinct authors in sample
Gene link
PAX6
Limited
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic inflammatory corneal disorder characterized by anterior stromal corneal opacification and vascularization of the peripheral cornea with potential central progression and subsequent reduction in visual acuity. Variable features include abnormalities of the iris, such as stromal defects and ectropion uveae, as well as foveal hypoplasia.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007848
- MeSH:C537022
- OMIM:148190
- UMLS:C1835698
Additional Mondo synonyms (2)
hereditary keratitis · keratitis, autosomal dominant
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Limited — PAX6
- LiteraturePresent
22,681 matched papers (13,285 in last 10 years) Source
- Phenotype characterisedPresent
18 HPO annotations (e.g. Macular hypoplasia; Hypoplasia of the fovea; Abnormal corneal limbus morphology) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 115 for broader category keratitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for PAX6.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
18
Associated phenotypes · MONDO:0007848
- Macular hypoplasia
- Hypoplasia of the fovea
- Abnormal corneal limbus morphology
- Limbal stem cell deficiency
- Cataract
Showing 5 of 18 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
22,681
22,681 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
22,681 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
13,285 in the last 10 years · low confidence
Phrase hits: 59 · MeSH hits: 0
Who's working on it?
234
Distinct author names in 59 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Cvekl A6 papers · 2004
The Department of Ophthalmology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. cvekl@aecom.yu.edu
Papers in Europe PMC - 02Chauhan BK5 papers · 2018
Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Papers in Europe PMC - 03Pearce WG4 papers · 1997
Department of Ophthalmology, University of Alberta, Edmonton.
Papers in Europe PMC - 04Walter MA4 papers · 1997Papers in Europe PMC
- 05Cveklova K3 papers · 2004Papers in Europe PMC
- 06Saunders GF3 papers · 2001Papers in Europe PMC
- 07Van Heyningen V3 papers · 2016
Department of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, UK.
Papers in Europe PMC - 08Yang Y3 papers · 2004Papers in Europe PMC
- 09
- 10Azuma N2 papers · 1999Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 115 trials are registered for keratitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
115 interventional trials matched keratitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: keratitis
115
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06999733·RECRUITING·A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT07329686·RECRUITING·Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Conditions: Herpes Simplex Keratitis · Corneal Neovascularization·Matched via name phrase
- NCT07773740·NOT YET RECRUITING·Autologous Plasma Rich in Growth Factors for Severe Dry Eye Disease
Conditions: Dry Eye Disease With Severe Keratitis·Matched via name phrase
- NCT07308938·NOT YET RECRUITING·Fluorometholone Study
Conditions: Keratitis Bacterial · Corneal Ulcer (Diagnosis)·Matched via name phrase
- NCT07568730·RECRUITING·A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT06451172·RECRUITING·Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
Conditions: Bacterial Keratitis · Antibiotic-resistant Bacteria · Infections, Bacterial · Corneal Diseases·Matched via name phrase
- NCT07394257·RECRUITING·Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis
Conditions: Bacterial Keratitis · Recalcitrant Infectious Keratitis · Corneal Ulcer·Matched via name phrase
- NCT05927428·RECRUITING·Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT05156151·ENROLLING BY INVITATION·Stromal Lenticule Implantation for Management of Herpetic Stromal Keratitis
Conditions: Stromal Keratitis·Matched via name phrase
- NCT06964269·RECRUITING·Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Conditions: Autoimmune Diseases · Dry Eye · Neurotrophic Keratitis·Matched via name phrase
- NCT06463678·NOT YET RECRUITING·Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis
Conditions: Fungal Keratitis·Matched via name phrase
- NCT07743489·NOT YET RECRUITING·RB-PDT for Fusarium Keratitis: The LUMIERE Study
Conditions: Fusarium Keratitis·Matched via name phrase
- NCT07452588·NOT YET RECRUITING·Effect of Sodium Chloride 5% Solution as an Adjuvant Treatment With Antimicrobial Therapy in the Treatment of Bacterial Infectious Keratitis
Conditions: Infectious Keratitis · Adjuvant Treatment Bacterial Infectious Keratitis · Sodium Chloride 5% Solution·Matched via name phrase
- NCT06975748·RECRUITING·A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT06213649·RECRUITING·Parasitic Ulcer Treatment Trial
Conditions: Acanthamoeba Keratitis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 25 · after dedupe 25 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 25 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (25)
- ctis·2025-525073-37-00·Revoked·A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive
skipped — LLM skipped (--skip-llm)
- ctis·2025-524313-86-00·11·A single center study to evaluate the safety and tolerability of oral Azathioprine in patients with ADPKD
skipped — LLM skipped (--skip-llm)
- ctis·2025-522343-18-00·Authorised, recruiting·A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524899-40-00·Authorised, ongoing·A First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MR-L45 in Healthy Adults
skipped — LLM skipped (--skip-llm)
- ctis·2025-523284-37-00·Authorised, ongoing·CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES
skipped — LLM skipped (--skip-llm)
- ctis·2025-522099-10-00·Authorised, ongoing·Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)
skipped — LLM skipped (--skip-llm)
- ctis·2025-522609-39-00·Authorised, recruiting·Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517393-13-00·Authorised, recruiting·A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
skipped — LLM skipped (--skip-llm)
- ctis·2025-521276-59-00·Authorised, recruiting·STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-521567-12-00·Authorised·Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519772-10-00·Authorised·Phase IIB Clinical Trial to evaluate the efficacy and safety of Allogeneic Mesenchymal Stem Cell (MSC) eye injection treatment as therapy for Graft-versus-Host Disease (GvHD) refractory to conventional treatments
skipped — LLM skipped (--skip-llm)
- ctis·2024-517143-31-00·Expired·A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-516095-15-00·Revoked·A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.
skipped — LLM skipped (--skip-llm)
- ctis·2024-518969-98-00·Cancelled·A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517864-49-01·Authorised, ongoing·Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi- centre, 2 parallel arms randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-515734-32-00·Authorised, ongoing·Safety of rotigotine in patients with autosomal dominant polycystic kidney disease - ETERNAL-PKD
skipped — LLM skipped (--skip-llm)
- ctis·2024-513828-42-00·Expired·CERICA - CERebrolysin In CADASIL - A randomized, double-blind, single-centre, two-period cross-over, placebo-controlled trial on safety and efficacy in patients with genetically proven CADASIL
skipped — LLM skipped (--skip-llm)
- ctis·2024-512491-35-00·Authorised, ongoing·Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI
skipped — LLM skipped (--skip-llm)
- ctis·2024-512544-27-00·Cancelled·Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease
skipped — LLM skipped (--skip-llm)
- ctis·2023-506290-35-00·Authorised, ongoing·Osprey: An Open-label Study to Investigate the Safety, Tolerability, and Exposure of Single Ascending Doses of the Antisense Oligonucleotide STK-002 in Patients with Autosomal Dominant Optic Atrophy
skipped — LLM skipped (--skip-llm)
- ctis·2023-508907-19-00·Cancelled·A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate Safety and Efficacy of Two Different Dosages of Isocyclosporin A Eye Drop Solution Versus Vehicle in Adult Patients with Atopic Keratoconjunctivitis (AKC).
skipped — LLM skipped (--skip-llm)
- ctis·2023-505890-34-00·Expired·Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease
skipped — LLM skipped (--skip-llm)
- ctis·2023-508743-43-00·Cancelled·Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
skipped — LLM skipped (--skip-llm)
- ctis·2022-501398-38-00·Authorised, recruiting·CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
skipped — LLM skipped (--skip-llm)
- ctis·2022-500210-26-00·Authorised, ongoing·HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Autosomal dominant keratitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Autosomal dominant keratitis" OR "Hereditary keratitis" OR "keratitis, autosomal dominant") OR ("PAX6" OR "PAX6 syndrome" OR "PAX6-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autosomal dominant keratitis" OR "Hereditary keratitis" OR "keratitis, autosomal dominant"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"keratitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (22681) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T19:54:24.814Z
